ProPhase Labs, Inc. Finite-Lived Intangible Assets, Net
ProPhase Labs, Inc. (PRPH) had Finite-Lived Intangible Assets, Net of $5.88 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsNet · last filed 2026-08-19
- 2026-06-30: Finite-Lived Intangible Assets, Net $5.88M.
- 2026-03-31: Finite-Lived Intangible Assets, Net $6.52M.
- 2025-12-31: Finite-Lived Intangible Assets, Net $7.17M.
- 2025-09-30: Finite-Lived Intangible Assets, Net $7.81M.
| Period end | Finite-Lived Intangible Assets, Net |
|---|---|
| 2026-06-30 | $5.88M 10-Q · filed 2026-08-19 |
| 2026-03-31 | $6.52M 10-Q/A · filed 2026-07-09 |
| 2025-12-31 | $7.17M 10-Q · filed 2026-08-19 |
| 2025-09-30 | $7.81M 10-Q · filed 2025-11-19 |
| 2025-06-30 | $8.46M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $9.10M 10-Q · filed 2025-05-20 |
| 2024-12-31 | $9.75M 10-K · filed 2026-06-01 |
| 2024-09-30 | $10.40M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $11.04M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $11.69M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $12.33M 10-K · filed 2025-04-01 |
| 2023-09-30 | $13.02M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $13.77M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $14.52M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $8.47M 10-K · filed 2024-03-29 |
| 2022-09-30 | $8.89M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $9.43M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $10.14M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $10.85M 10-K · filed 2023-03-29 |
| 2021-09-30 | $11.56M 10-Q · filed 2021-11-12 |
| 2020-12-31 | $1.23M 10-K · filed 2022-03-31 |
| 2014-12-31 | $0.00 10-K · filed 2015-03-27 |
| 2014-09-30 | $0.00 10-Q · filed 2014-11-13 |
| 2014-06-30 | $3.58M 10-Q · filed 2014-08-12 |
| 2014-03-31 | $3.58M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $3.58M 10-K · filed 2015-03-27 |
| 2013-09-30 | $3.58M 10-Q · filed 2013-11-13 |
| 2013-06-30 | $3.58M 10-Q · filed 2013-08-13 |
| 2013-03-31 | $3.58M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $3.58M 10-K · filed 2014-03-27 |
| 2012-09-30 | $3.58M 10-Q · filed 2012-11-14 |
| 2012-06-30 | $3.58M 10-Q · filed 2012-08-13 |
| 2012-03-31 | $3.58M 10-Q · filed 2012-05-11 |
| 2011-12-31 | $3.58M 10-K · filed 2013-03-28 |
| 2011-09-30 | $3.58M 10-Q · filed 2011-11-14 |
| 2011-06-30 | $3.58M 10-Q · filed 2011-08-12 |
| 2010-12-31 | $3.58M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |